Difficult to treat rheumatoid arthritis in a comprehensive evaluation program: frequency according to different objective evaluations
- PMID: 37269430
- DOI: 10.1007/s00296-023-05349-8
Difficult to treat rheumatoid arthritis in a comprehensive evaluation program: frequency according to different objective evaluations
Abstract
Difficult-to-treat Rheumatoid Arthritis (RA-D2T) is a condition in which patients do not achieve the treatment target despite multiple advanced therapies, more others features. Aims: to estimate the frequency of RA-D2T in a cohort comprehensively evaluated (clinical, serology, imaging), and to analyze the associated characteristics. In a second part, the frequency of RA-D2T after 1 year of follow-up, analyzing the predictive variables at baseline and therapeutic behavior. Cross-sectional and prospective study, consecutive RA were included, then those who completed the one-year follow-up were evaluated. RA-D2T frequency was estimated (DAS28-CDAI-SDAI-Ultrasonography (US)-HAQ) at baseline and 1 year. The variables associated and those baseline predictive characteristics of D2T at 1 year, and their independent association by logistic regression were analyzed. The treatment approach was described. Two hundred seventy-six patients completed the evaluation, frequency of RA-D2T (all scores): 27.5%. Anemia, RF high titers and higher HAQ score were independent associated. At year, 125 competed follow-up. RA-D2T (all scores): 33%, D2T-US and D2T-HAQ were 14 and 18.4% (p 0.001). Predictive baseline characteristics D2T (all score): ACPA + (OR: 13.7) and X-ray erosion (OR: 2.9). D2T-US: X-ray erosion (OR: 19.7). Conventional DMARDs, corticosteroids and TNF-blockers were the drugs most used by D2T patients, Jaki were the most used in the switch. We showed different frequencies of RA-D2T according to different objective parameters (scores, images) and their association with patient characteristics. In turn, predictive variables (erosions-ACPA) for RA-D2T at 1 year were analyzed. It was shown that the Jaki were the most used drug in these patients.
Keywords: ACPA; Difficult to treat; Disease activity; Jak inhibitors; Rheumatoid arthritis; X-ray erosion.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Obesity and fibromyalgia are associated with Difficult-to-Treat Rheumatoid Arthritis (D2T-RA) independent of age and gender.Arthritis Res Ther. 2025 Jan 3;27(1):2. doi: 10.1186/s13075-024-03432-4. Arthritis Res Ther. 2025. PMID: 39754234 Free PMC article.
-
Difficult-to-treat rheumatoid arthritis: what have we learned and what do we still need to learn?Rheumatology (Oxford). 2025 Jan 1;64(1):65-73. doi: 10.1093/rheumatology/keae544. Rheumatology (Oxford). 2025. PMID: 39383505 Free PMC article. Review.
-
Is Baricitinib Effective and Safe for Patients with Difficult-to-Treat Rheumatoid Arthritis? Comparative Data with the Rheumatoid Arthritis Group of Rheumatoid Arthritis Not Difficult to Treat.Med Princ Pract. 2025;34(1):75-86. doi: 10.1159/000541488. Epub 2024 Sep 17. Med Princ Pract. 2025. PMID: 39288740 Free PMC article.
-
Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry.Arthritis Res Ther. 2022 Mar 1;24(1):61. doi: 10.1186/s13075-022-02744-7. Arthritis Res Ther. 2022. PMID: 35232462 Free PMC article.
-
A Review of Difficult-to-Treat Rheumatoid Arthritis: Definition, Clinical Presentation, and Management.Curr Rheumatol Rep. 2023 Dec;25(12):285-294. doi: 10.1007/s11926-023-01117-6. Curr Rheumatol Rep. 2023. PMID: 37776482 Review.
Cited by
-
Unmet Needs and Current Challenges of Rheumatoid Arthritis: Difficult-to-Treat Rheumatoid Arthritis and Late-Onset Rheumatoid Arthritis.J Clin Med. 2024 Dec 13;13(24):7594. doi: 10.3390/jcm13247594. J Clin Med. 2024. PMID: 39768516 Free PMC article. Review.
-
Obesity and fibromyalgia are associated with Difficult-to-Treat Rheumatoid Arthritis (D2T-RA) independent of age and gender.Arthritis Res Ther. 2025 Jan 3;27(1):2. doi: 10.1186/s13075-024-03432-4. Arthritis Res Ther. 2025. PMID: 39754234 Free PMC article.
-
Difficult-to-treat rheumatoid arthritis: what have we learned and what do we still need to learn?Rheumatology (Oxford). 2025 Jan 1;64(1):65-73. doi: 10.1093/rheumatology/keae544. Rheumatology (Oxford). 2025. PMID: 39383505 Free PMC article. Review.
-
The Extent and Nature of Functional Limitations According to the Health Assessment Questionnaire Disability Index in Patients with Rheumatoid Arthritis and Severe Functional Disability.J Clin Med. 2024 Jan 10;13(2):379. doi: 10.3390/jcm13020379. J Clin Med. 2024. PMID: 38256511 Free PMC article.
-
Characteristics of patients with difficult-to-treat rheumatoid arthritis: a descriptive retrospective cohort study.Adv Rheumatol. 2024 Aug 6;64(1):55. doi: 10.1186/s42358-024-00396-6. Adv Rheumatol. 2024. PMID: 39107865
References
-
- Aletaha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis. JAMA. https://doi.org/10.1001/jama.2018.13103 - DOI - PubMed
-
- Smolen JS, Breedveld FC, Burmester GR et al (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2015-207524 - DOI - PubMed
-
- Smolen JS, Landewé RBM, Bergstra SA et al (2022) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. https://doi.org/10.1136/ard-2022-223356 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical